Search





Search





Novo Nordisk A/S

NVO

Add to Watchlist

38.620USD

+0.450+1.18%

Close 09-24 16:00（ET）

170.66BMarket Cap

9.03P/E TTM

After-hours 19:00 (ET)38.620USD+0.005+0.01%

Novo Nordisk A/S

38.620

+0.450+1.18%

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

TradingKey Chart

Intraday

30m

Today

+1.18%

5 Days

-10.58%

1 Month

-17.69%

6 Months

+11.15%

Year to Date

-19.41%

1 Year

-30.19%

Key Figures

37.950Open

39.140High

3.69MVolume

9.03P/E TTM

11.25P/E Dynamic

1.892Dividend TTM

0.08%Turnover Ratio

38.170Prev. Close

37.920Low

141.98MTurnover

11.65P/E Static

5.05P/B

4.90%Div Yield TTM

24.13%ROA

60.42952wk High

62.33Volume Ratio

14.65BNet Profit

4.42BShares

4.2743EPS TTM

0.79Beta

73.77%ROE

34.23452wk Low

3.20%Amplitude

78.21%Gross Margin

170.66BMarket Cap

-4.16Reward/Risk

2.93%Risk Rate

Novo Nordisk A/S News

Recent

Analysis

Novo Nordisk A/S Stock (NVO) Closed Down by 3.12% on Sep 23: Key Drivers Unveiled

• Novo Nordisk shares dropped following disappointing long-term revenue growth targets. • Intensifying competition, patent cliff risks, and market share losses weighed heavily. • Technical indicators show sell signals with an RSI of 27.877.

TradingKeyWed, Sep 23

Novo Nordisk A/S Stock (NVO) Moved Down by 7.86% on Sep 21: A Full Analysis

• Novo Nordisk faced downward pressure after its Capital Markets Day strategic update. • Eli Lilly competition and patent expirations raised concerns over market dominance. • The MACD value of negative 0.874 indicates a sell signal.

TradingKeyMon, Sep 21

Novo Nordisk A/S Stock (NVO) Moved Up by 3.02% on Sep 17: What Signal Does It Send?

• Novo Nordisk partnered with Orbis Medicine for AI-driven oral cardiometabolic drug discovery. • European regulators issued a favorable marketing recommendation for Frehemgo in hemophilia A. • The company reported $46.70B in annual revenue and $15.48B in net profit.

TradingKeyThu, Sep 17

Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement

• Novo Nordisk halted two late-stage Phase 3 ziltivekimab trials due to futility. • Positive STEP Young trial results for semaglutide failed to lift sentiment. • Technical indicators show a MACD sell signal and oversold Williams %R.

TradingKeyTue, Sep 8

Novo Nordisk A/S Stock (NVO) Moved Up by 3.17% on Sep 2: What Signal Does It Send?

• Novo Nordisk launched its oral weight-loss treatment in Germany and Greater China. • The company continues executing its multi-billion share repurchase program supporting shareholders. • Annual revenue reached $46.70B with net profit totaling $15.48B.

TradingKeyWed, Sep 2

Novo Nordisk A/S Stock (NVO) Moved Down by 3.32% on Aug 26: Drivers Behind the Movement

• Novo Nordisk faced downside pressure due to margin compression and pricing dynamics. • Intense competition from rival therapies heightened sensitivity to market share trends. • The stock reported an annual revenue of $46.70B and net profit of $15.48B.

TradingKeyWed, Aug 26

TradingKey Stock Score of Novo Nordisk A/S

Novo Nordisk A/S's Score

0.04vs previous score

Forecast6.86

Financial Health9.20

Technical4.21

Valuation Dimensions8.94

Institutional Confidence3.00

Risk Assessment6.75

Media Coverage

Coverage Level

Very Low

Very High

Negative-

Analyst Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

HoldCurrent Rating

49.107Target Price

+28.65%Upside Space

Current Rating	2026-09	2026-08	2026-07	2026-06	2026-05	2026-04	2026-03	2026-02
Strong Buy	2	2	2	2	1	1	1	1
Buy	2	2	2	2	4	4	3	3
Hold	10	10	10	10	7	6	6	6
Sell	0	0	0	0	1	1	1	1
Strong Sell	0	0	0	0	0	1	1	1

Novo Nordisk A/S Technical Analysis

15m

30m

15m

D

Technical Indicators

Strong sell

Summary

Sell

Moving Average

Strong sell

Financial Indicators

Currency: USD

Quarterly

Quarterly

Annual

Relevant data have not been disclosed by the company yet.

Currency: USD

Quarterly

Quarterly

Annual

Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date

Reporting Period

2026Q2

Earnings / Forecast

0.74/0.77

Revenue / Forecast

12.21B/11.11B

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.

Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.

Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.

SectorPharmaceuticals

Ticker SymbolNVO

Number of employees76302

CountryDenmark